Get the Stockscreener App
136.13
0.26%
0.35
After Hours:
136.24
0.11
+0.08%
Insulet Corp stock is traded at $136.13, with a volume of 1.06M.
It is up +0.26% in the last 24 hours and down -4.84% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$135.78
Open:
$135.78
24h Volume:
1.06M
Relative Volume:
0.66
Market Cap:
$9.44B
Revenue:
$2.90B
Net Income/Loss:
$302.80M
P/E Ratio:
31.68
EPS:
4.2965
Net Cash Flow:
$387.80M
1W Performance:
-3.18%
1M Performance:
-4.84%
6M Performance:
-36.98%
1Y Performance:
-57.93%
1-Day Range:
$134.48
$138.06
1-Week Range:
$134.48
$142.04
52-Week Range:
$126.40
$354.88
Insulet Corp Stock (PODD) Company Profile
Name
Insulet Corp
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
136.13 | 9.44B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corp Stock (PODD) Latest News
Insulet Corporation (PODD) Stock Price, News, Quote & History - Yahoo! Finance Canada
PODD5061895 Bond Profile: Coupon and Redemption - TradingView
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum - Yahoo Finance
Transcript : Insulet Corporation Presents at Bernstein Insights - marketscreener.com
Insulet at Bernstein healthcare forum: growth, retention and new AID push - Investing.com
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks? - inkl.com
Insulet Corporation (PODD) Stock Forecasts - Yahoo Finance
Insulet (PODD) Refinances $475 Million Term Loans and Expands Re - gurufocus.com
Insulet Reprices $475 Million Term Loans, Expands Revolver to $750 Million in Credit Amendment - TradingView
Insulet (PODD) cuts interest margins on $475M loan and expands credit access - Stock Titan
Insulet Corporation Amends And Increases Credit Agreement, Refinances $475 Million Term Loans, And Expands Revolving Credit Facility To $750 Million - marketscreener.com
Insulet stock gains as Bank of America stake and guidance highlight upside potential - AD HOC NEWS
Insulet Corporation(NasdaqGS: PODD) dropped from FTSE All-World Index - marketscreener.com
Insulet stock heads into the open after a modest September 18, 2026 gain - AD HOC NEWS
Insulet stock gains support from Bank of America stake and strong Q1 2026 figures - AD HOC NEWS
Insulet Stock Price Forecast. Should You Buy PODD? - StockInvest.us
The maker of Omnipod will speak at a healthcare forum Sept. 24 - Stock Titan
The largest med-device firms in Mass. collectively increased revenue in 2025 - The Business Journals
Insulet Corporation (PODD) Adopts Nonqualified Deferred Compensa - GuruFocus
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status - Yahoo Finance
Insulet stock heads into the open after a modest decline - AD HOC NEWS
Insulet Faces Class Action Lawsuit Over Product Safety Issues - Intellectia AI
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Important Notice to Long-Term Shareholders of FuelCell - GlobeNewswire
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Insulet Weighs Major Acton Expansion as State Offers $40M in Incentives - Boston Real Estate Times
Grabar Law probes Bloom Energy, Cogent, Insulet, Primoris for fiduciary breaches - scanx.trade
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Insulet Corp (PODD) Shares Fall 3.1% -- What GF Score of 77 Tells Investors - GuruFocus
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet at Wells Fargo conference: guidance cut meets long-term optimism - investing.com
Is Insulet Corp (PODD) a Bargain After 3.5% Drop? GF Value Says Undervalued - GuruFocus
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Why Insulet (PODD) Stock Is Down Today - Quiver Quantitative
State offers record $40M package to keep medical device company in Mass. - NBC Boston
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now? - Yahoo Finance
Artisan Sold Insulet (PODD) Due to Competition Concerns - Yahoo Finance
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report? - Yahoo Finance
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks - Yahoo Finance
Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds - Yahoo Finance
Is Insulet (PODD) Undervalued On Lawsuit And Device Correction Risks? - Yahoo Finance
Important Notice to Long-Term Shareholders of Hub Group, - GlobeNewswire
Insulet crushed its most recent earnings, but the market's focus on its slightly lowered outlook has presented a buying opportunity - CNBC
PODD CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - TMX Newsfile
Insulet Corporation: Strong Growth Meets A New Execution Problem (NASDAQ:PODD) - Seeking Alpha
PODD DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Insulet Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 31 Deadline in Securities Class ActionPODD - TMX Newsfile
MONDAY PODD INVESTOR DEADLINE: Insulet Corporation - GlobeNewswire
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law - GlobeNewswire
PODD INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class ActionContact Levi & Korsinsky - PR Newswire
Is Wall Street Bullish or Bearish on Insulet Stock? - Yahoo Finance
Insulet Corp Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):